title: Successfully treated nosocomial Stenotrophomonas maltophilia bacteremia following desensitization to trimethoprim-sulfamethoxazole.
abstract: Stenotrophomonas maltophilia has emerged as an important cause of morbidity and mortality in hospitalized patients. Because trimethoprim-sulfamethoxazole (TMP-SMX) remains the most effective drug for the treatment of S. maltophilia infections, desensitization should be considered in patients with hypersensitivity to TMP-SMX.
authors: Infectious Diseases and Clinical Microbiology Department, Cerrahpasa Medical Faculty, University of Istanbul, Turkey. mesutmd@hotmail.com
authors: Mesut
authors: M
authors: Yilmaz
authors: Aykut Ferhat
authors: AF
authors: Celik
authors: Ali
authors: A
authors: Mert
mesh_terms: D016470:Bacteremia / Q000188:drug therapy*; D002761:Cholangitis / Q000150:complications; D003428:Cross Infection / Q000188:drug therapy*; D003888:Desensitization, Immunologic; D024881:Drug Resistance, Bacterial / Q000187:drug effects; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D020615:Stenotrophomonas maltophilia / Q000187:drug effects* / Q000472:pathogenicity; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000276:immunology* / Q000627:therapeutic use
chemical_list: D015662:Trimethoprim, Sulfamethoxazole Drug Combination